ClinicalTrials.gg
CompletedNCT06982209Updated Aug 14, 2026

ANI-Guided Anesthetic Desflurane Consumption

An interventional study of Analgesia/Nociception Index (ANI) in Postoperative Pain, General Anesthesia and Laparoscopic Cholecystectomy, sponsored by Wonkwang University Hospital. Completed at 1 site in South Korea. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Wonkwang University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

General anesthesia requires precise titration of inhaled anesthetics like desflurane and opioids like remifentanil to balance sedation, analgesia, and hemodynamic stability. The Analgesia/Nociception Index (ANI), derived from heart rate variability (HRV), quantifies parasympathetic tone to assess nociception-antinociception balance on a 0-100 scale, with lower values indicating nociceptive stress. ANI analyzes high-frequency HRV components, reflecting parasympathetic inhibition during painful stimuli, making it a reliable indicator of intraoperative nociception. Studies validate the utility of ANI in detecting nociceptive events during laparoscopic surgery. ANI-guided opioid titration reduces opioid consumption and stabilizes hemodynamics, enhancing perioperative outcomes.

Read the detailed description

Study Design This prospective, single-center, randomized controlled trial receives approval from the [Institutional Review Board Name] (Approval No. 2024-01-05-21-004). Written informed consent is obtained from all participants.

Participants Eligible patients are aged 19-65 years, American Society of Anesthesiologists (ASA) physical status I-II, and are scheduled for elective laparoscopic cholecystectomy under general anesthesia. Exclusion criteria include chronic pain, preoperative opioid use, cardiac arrhythmias, autonomic dysfunction, or contraindications to desflurane or remifentanil.

Randomization and Blinding Patients are randomized (1:1) to Analgesia/Nociception Index (ANI)-guided or standard care groups using a computer-generated sequence in blocks of four. Group allocation is concealed in opaque, sealed envelopes, which are opened before induction. Anesthesiologists remain unblinded due to ANI monitoring requirements, but patients and postoperative outcome assessors remain blinded to reduce bias.

Anesthesia Protocol Anesthesia is induced with propofol (2 mg/kg) and rocuronium (0.6 mg/kg). Maintenance includes desflurane and remifentanil (0.1 µg/kg/min continuous infusion). Ventilation maintains normocapnia (end-tidal Carbon dioxide: 35-40 mmHg). Bispectral index (BIS) is monitored to ensure hypnotic depth (target: 40-60).

Novel Metrics

In addition to standard intraoperative management, the following novel physiological and recovery-related metrics are assessed to enhance the evaluation of ANI-guided anesthesia:

  • ∆ANI (Dynamic Change of ANI): The percentage change in ANI at specific surgical stimuli (e.g., skin incision, trocar insertion) is recorded as: ∆ANI = (ANI_post - ANI_pre) / ANI_pre × 100.
  • Autonomic Nervous System Indicators:
  • Heart Rate Variability (HRV): High Frequency (HF) and Low Frequency (LF)/HF ratio are calculated at baseline, mid-surgery, and end-surgery. Continuous beat-to-beat blood pressure (BP) and lead II electrocardiogram (ECG) are recorded noninvasively for 5 minutes using the equipment. HRV parameters are extracted using Software.
  • Baroreflex Sensitivity (BRS): BRS is assessed pre-induction and intraoperatively. It is quantified using the spontaneous sequence method with regression analysis between Blood Pressure and respiratory rate intervals, measured with the equipment and analyzed with HRV Software.

Recovery Room Metrics

  • Post-Anesthesia Care Unit (PACU) Length of Stay (LOS): Time from PACU entry to discharge readiness is recorded.
  • Additional Analgesic Requirement: Any supplemental pain medication and dosage are recorded during PACU stay.
  • Postoperative Nausea and Vomiting (PONV): Incidence is recorded within the first two postoperative hours.

Patient-Reported Outcomes

  • Satisfaction Scores (Visual analogue scale [VAS]0-10): Are assessed at PACU discharge and on postoperative day 1 (POD1).
  • ANI Group: Desflurane starts at 1 Minimum Alveolar Concentration (MAC) (\~6 Vol%) and is titrated in 0.1 MAC increments to maintain ANI 50-70 and BIS 40-60. ANI \<50 prompts an increase; ANI >70 prompts a decrease.
  • Control Group: Desflurane is titrated based on vital signs and BIS 40-60 per institutional protocol.

ANI is monitored using the ANI monitor in both groups, but only guides adjustments in the ANI group. Hemodynamic data are recorded every 5 minutes.

Emergence and Recovery At the end of the surgery, desflurane and remifentanil are discontinued. Neuromuscular blockade is monitored using Train-of-Four (TOF) stimulation. When TOF count reaches ≥2, sugammadex (2 mg/kg) is administered to reverse rocuronium. Extubation occurs when TOF ratio >0.9, with adequate spontaneous breathing and responsiveness to verbal commands. Emergence time is recorded as time from anesthetic cessation to eye opening.

Outcome Measures

  • Primary Outcome: Mean end-tidal desflurane concentration (Vol%).
  • Secondary Outcomes:
  • Emergence time (min).
  • Postoperative pain (VAS, 0-10) at 30 min post-extubation.
  • Intraoperative hemodynamic stability (hypertension [Mean arterial pressure > 100 mmHg] or tachycardia [HR >100 bpm]).
  • ∆ANI at surgical stimuli.
  • HRV metrics (HF, LF/HF ratio).
  • Baroreflex Sensitivity (BRS).
  • PACU LOS.
  • Requirements and dosage of additional analgesics in PACU.
  • Incidence of PONV within 2 hours post-op.
  • Patient satisfaction (PACU discharge and postoperative day 1).
02

Conditions studied

  • Postoperative Pain
  • General Anesthesia
  • Laparoscopic Cholecystectomy

Browse trials for

03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's enrollment of 125 is above the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Wonkwang University Hospital is the lead sponsor of 26 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged 19-65 years, (ASA) physical status I-II, scheduled for elective laparoscopic cholecystectomy under general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • chronic pain, preoperative opioid use, cardiac arrhythmias, autonomic dysfunction, or to desflurane or remifentanil.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    ANI-guided group

    Desflurane started at 1 MAC (\~6 Vol%), titrated in 0.1 MAC increments to maintain ANI 50-70 and BIS 40-60. ANI \<50 prompted an increase; ANI \>70 prompted a decrease

    Device: Analgesia/Nociception Index (ANI)

  • Active comparator
    Control group

    Desflurane was titrated based on vital signs (heart rate, blood pressure) and BIS 40-60, per institutional protocol.

    Device: Analgesia/Nociception Index (ANI)

Interventions

  • DeviceAnalgesia/Nociception Index (ANI)

    ANI was monitored using the ANI monitor (MetroDoloris, France) in both groups, but only guided adjustments in the ANI group

06

What researchers measure

Primary outcomes

  1. Mean End-Tidal Desflurane Concentration

    The average end-tidal desflurane concentration (Vol%) during maintenance of general anesthesia, measured using continuous gas monitoring. Desflurane delivery is titrated based on ANI (Analgesia/Nociception Index) in the intervention group and based on vital signs in the control group.

    Time frame: From induction of anesthesia to end of surgery (approximately 60 minutes)

Secondary outcomes

  1. Emergence Time

    Time from discontinuation of anesthetics to eye opening upon verbal command, recorded in minutes.

    Time frame: At the end of surgery until eye opening (approximately 5-15 minutes)

  2. Post-Anesthesia Care Unit (PACU) Length of Stay

    Time from PACU admission to discharge readiness, measured in minutes.

    Time frame: From PACU entry to PACU discharge criteria fulfillment (approximately 30-90 minutes)

  3. Additional Analgesic Requirement in PACU

    Number of patients requiring additional analgesics in PACU and total morphine-equivalent dose administered.

    Time frame: During PACU stay (up to 2 hours after surgery)

  4. Incidence of Postoperative Nausea and Vomiting (PONV)

    Presence of nausea or vomiting events recorded within the first two postoperative hours.

    Time frame: Within 2 hours after surgery

  5. Patient Satisfaction

    Patient-reported satisfaction using a Visual Analog Scale (0-10) at PACU discharge and on postoperative day 1.

    Time frame: At PACU discharge and 24 hours postoperatively (POD1)

07

Study locations

1 site
  • Wonkwang University School of Medicine Hospital
    Iksan, Jeollabuk-do 54538, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Jul 2026, 0 months.

Of 2,089 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 0 months is below that.

Counting every sponsor, half of 2,102 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 21, 2025
StartActual
Jul 2, 2026
Primary completionActual
Jul 12, 2026
CompletionActual
Aug 12, 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06982209
Lead sponsor
Wonkwang University Hospital
Responsible party
Cheol Lee,MD,PhD, (Professor, Wonkwang University Hospital) — Principal investigator
First posted
May 21, 2025
Start date
Jul 2, 2026
Primary completion
Jul 12, 2026
Completion
Aug 12, 2026
Last update
Aug 14, 2026

Study contacts

Cheol Lee, M.D.,Ph.D
principal investigator · Wonkwang University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion